- Home
- CVAC vs ABCL Comparison
CVAC vs ABCL Comparison
Compare CVAC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- ABCL
- Stock Information
- Founded
- CVAC 2000
- ABCL 2012
- Country
- CVAC Germany
- ABCL Canada
- Employees
- CVAC N/A
- ABCL N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- ABCL Biotechnology: Pharmaceutical Preparations
- Sector
- CVAC Health Care
- ABCL Health Care
- Exchange
- CVAC Nasdaq
- ABCL Nasdaq
- Market Cap
- CVAC 818.8M
- ABCL 818.2M
- IPO Year
- CVAC 2020
- ABCL 2020
- Fundamental
- Price
- CVAC $3.30
- ABCL $3.03
- Analyst Decision
- CVAC Hold
- ABCL Buy
- Analyst Count
- CVAC 3
- ABCL 3
- Target Price
- CVAC $10.00
- ABCL $8.00
- AVG Volume (30 Days)
- CVAC 617.5K
- ABCL 3.8M
- Earning Date
- CVAC 11-12-2024
- ABCL 02-27-2025
- Dividend Yield
- CVAC N/A
- ABCL N/A
- EPS Growth
- CVAC N/A
- ABCL N/A
- EPS
- CVAC N/A
- ABCL N/A
- Revenue
- CVAC $70,565,734.00
- ABCL $32,962,000.00
- Revenue This Year
- CVAC $742.57
- ABCL N/A
- Revenue Next Year
- CVAC N/A
- ABCL $37.26
- P/E Ratio
- CVAC N/A
- ABCL N/A
- Revenue Growth
- CVAC 75.11
- ABCL N/A
- 52 Week Low
- CVAC $2.22
- ABCL $2.34
- 52 Week High
- CVAC $5.28
- ABCL $5.26
- Technical
- Relative Strength Index (RSI)
- CVAC 39.12
- ABCL 45.64
- Support Level
- CVAC $3.53
- ABCL $2.88
- Resistance Level
- CVAC $3.72
- ABCL $3.60
- Average True Range (ATR)
- CVAC 0.18
- ABCL 0.20
- MACD
- CVAC -0.06
- ABCL -0.01
- Stochastic Oscillator
- CVAC 10.96
- ABCL 20.83
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.